Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study. Patients who rel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, Brian G. M.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643003/
https://ncbi.nlm.nih.gov/pubmed/26384354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-643320
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares